Download vCard

+1 202 637 3660

+1 202 637 5910

Stephen J. Immelt
CEO, Washington, D.C.
Share on Facebook Share on LinkedIn Share on Twitter Bookmark this page Email This Page Print This Page Export to Word

Stephen J. Immelt is the CEO of Hogan Lovells and divides his time between the firm’s London and Washington, D.C. offices. Prior to taking on this position, Steve served as the Global Co-Head of Hogan Lovells' Litigation and Arbitration practice and as a member of the International Management Committee. Steve has served in a number of other leadership positions during his time at the firm.

Steve’s legal practice has focused primarily on complex enforcement litigation relating to a range of healthcare issues. For more than 20 years, Steve has represented pharmaceutical companies, medical device companies, academic health centers and medical schools, clinical laboratories, and other providers of healthcare in connection with a wide variety of governmental investigations, both civil and criminal in nature, involving issues arising under federal and state laws that govern healthcare providers. These matters have included a wide range of issues arising under the Anti-Kickback Act, the Food Drug and Cosmetics Act, the Foreign Corrupt Practices Act, and the False Claims Act. Steve has particular experience in off-label and financial relationship cases. He has also handled a variety of issues arising from funded research, both in terms of compliance with regulatory requirements governing the use of research funds and allegations of misconduct by researchers.

Steve speaks and writes frequently on healthcare fraud and compliance issues and has been recognized nationally for his expertise in these areas.

Steve served as an Assistant U.S. Attorney for the District of Maryland from 1979 through 1983. During his service in this office, he participated in numerous criminal trials dealing with political corruption, fraud, tax evasion, and conspiracy charges. Steve returned to private practice in 1983 and joined the firm in 1989.

  • Representation of pharmaceutical and biologics companies in connection with numerous federal and state investigations of sales and marketing; pricing; Medicaid rebate; and FDCA promotional issues, including off-label marketing.
  • Representation of a major orthopedic device company in connection with a criminal and civil investigation of sales and marketing practices. Resolution included negotiation of a deferred prosecution agreement, civil settlement agreement, and corporate integrity agreement.
  • Representation of medical device companies in defending False Claims Act matters arising from reimbursement, FDCA promotional (including off-label marketing), and fraud and abuse theories.
  • Representation of universities, academic health centers, and hospitals in connection with False Claims Act litigation involving allegations of billing, research, and program fraud.
  • Representation of medical device companies in investigations of business activities in China.
  • Representation of healthcare companies, including healthcare insurers, in a variety of matters involving alleged violations of federal and state laws, typically including False Claims Act allegations.
  • Representation of an institutional pharmacy provider with respect to Medicare Part D and related issues.
  • Numerous assignments relating to the development of compliance plans for corporate and institutional entities, including for operations outside the United States.
  • Representation of a university in a False Claims Action relating to compliance with incentive compensation regulations.
  • Representation of a software developer in a False Claims Action relating to allegedly inaccurate pricing submissions to GSA.

"Fraud and Abuse Developments Affecting Life Sciences Companies," AHLA/HCCA Fraud and Compliance Forum.
"Back to the Future: Anti-Fraud Enforcement Trends: The Prosecutor, Whistleblower and Defense Perspectives," American Health Lawyers Association Fraud and Compliance Forum, Keynote Panelist.

"Compliance Lessons Learned From the Medical Denle Experience," Pharmaceutical Regulatory and Compliance Congress, Panelist.

"Recent Developments in FCA Enforcement," National Institute on the Civil False Claims Act and Qui Tam, Panelist.

"Ethics Debate Regarding Physician Relationships with Industry," Society of Thoracic Surgeons, Panelist.

"Conducting Internal Investigations," AAMC Compliance Officers Forum, Presenter.

"Medical Device Enforcement Developments," ABA Health Care Fraud Institute, Presenter.

"A Critical Analysis of Deferred Prosecution Agreements and Federal Monitors in the Health Care Industry: Are They Working?" Seton Hall Law School Symposium, Panelist.

"Pharmaceutical Compliance Forum: Clinical Trials Case Study," Eighth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum, Washington, D.C.

"Overview of US Enforcement and Regulatory Trends," International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum, Brussels, Belgium.

Hogan Lovells Publications
19 April 2013 "OIG releases revised and expanded self-disclosure protocol." Health Alert, Hogan Lovells

07 January 2013 "Focus on Life Sciences Industry Trends for 2013." Life Sciences Alert, Hogan Lovells

19 October 2011 "OIG Releases Advisory Opinion Demonstrating Continued Concern with Physician-Owned Companies." Health Alert, Hogan Lovells

10 June 2011 "Senate asks OIG to probe physician-owned distributors." Health Alert, Hogan Lovells

09 July 2010 "OIG Settles Kickback Case with Physician-Owned Company for Leveraging Patient Referrals to Obtain Contract Business from Hospitals." Health, Hospitals, and Medical Devices Alert, Hogan Lovells

25 March 2010 "Health Reform Legislation Includes Significant Amendments to the False Claims Act and the Anti-Kickback Statute." Litigation Alert, Hogan & Hartson LLP

17 March 2010 "OIG Predicts Increased Scrutiny and Actions Against Individuals for Wrongdoing." Health Update, Hogan & Hartson LLP

19 February 2010 "Physician-Owned Companies." Health Update, Hogan & Hartson LLP

12 February 2008 "Foreign Corrupt Practices Act and the Healthcare Industry." Medical Device Update, Hogan & Hartson LLP

12 February 2008 "Foreign Corrupt Practices Act and the Healthcare Industry." Pharmaceutical and Biotechnology Update, Hogan & Hartson LLP

06 February 2008 "FCPA and the Healthcare Industry." Health Update, Hogan & Hartson LLP

24 February 2005 "Pharmaceutical Marketing Practices: European Authorities Tighten Controls." EU Bulletin, Hogan & Hartson LLP

Published Works
18 July 2005 "Building a Shield: Compliance Plans." International Comparative Legal Guide to: Pharmaceutical Advertising 2005, Global Legal Group

Litigation and Arbitration
Food, Drug, Medical Device and Agriculture
Investigations, White Collar and Fraud
Class Actions
Life Sciences
  • Government Investigations
  • False Claims Act Litigation
  • Reimbursement Litigation
  • Compliance Issues
  • The Food, Drug, and Cosmetic Act
  • General Business Litigation
J.D., cum laude, University of Maryland School of Law, 1977 B.A., cum laude, Yale University, 1974
  • Member, American Health Lawyers Association
  • Member, Health Law Section, American Bar Association
  • Member, National Association of College and University Attorneys
  • LMG Life Sciences, Life Sciences Star, 2012-2013
  • PLC Which Lawyer, Life Sciences
  • The International Who's Who of Business Crime Lawyers, 2008
  • The Best Lawyers in America, Criminal Defense: White Collar, 2008-2013; Business Litigation, 1995-2013; Commercial Litigation, 1995-2013; Bet-the-Company Litigation, 1995-2013 
  • Chambers USA, Litigation: General Commercial, 2004-2013; Health Care, 2006-2014
  • Maryland Super Lawyers, 2006-2014
BAR ADMISSIONS / QUALIFICATIONS District of Columbia Maryland New York
COURT ADMISSIONS Maryland Court of Appeals U.S. Court of Appeals, District of Columbia Circuit U.S. Court of Appeals, Second Circuit U.S. Court of Appeals, Fourth Circuit U.S. District Court, District of Columbia